1. Home
  2. FKWL vs TVRD Comparison

FKWL vs TVRD Comparison

Compare FKWL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Wireless Corp.

FKWL

Franklin Wireless Corp.

HOLD

Current Price

$2.32

Market Cap

33.0M

Sector

Utilities

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.10

Market Cap

27.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FKWL
TVRD
Founded
1981
2017
Country
United States
United States
Employees
N/A
12
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.0M
27.5M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
FKWL
TVRD
Price
$2.32
$2.10
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$6.00
$29.50
AVG Volume (30 Days)
27.2K
6.5M
Earning Date
05-15-2026
05-14-2026
Dividend Yield
1.10%
N/A
EPS Growth
94.12
N/A
EPS
N/A
N/A
Revenue
$46,086,901.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
49.65
N/A
52 Week Low
$2.28
$1.50
52 Week High
$5.48
$43.65

Technical Indicators

Market Signals
Indicator
FKWL
TVRD
Relative Strength Index (RSI) 29.99 39.82
Support Level $2.28 $1.50
Resistance Level $3.79 $4.38
Average True Range (ATR) 0.05 0.38
MACD 0.02 -0.09
Stochastic Oscillator 17.65 7.43

Price Performance

Historical Comparison
FKWL
TVRD

About FKWL Franklin Wireless Corp.

Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: